CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 190 enrolled
Drug / intervention
Keppra XR (Levetiracetam XR)drug
Likely dose
Keppra XR (Levetiracetam XR) 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00419393
NCT00419393Phase 3Completed
CompareCT.gov

An Open-label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-onset Seizures

UCB Pharma·interventional·Posted Jan 8, 2007·Updated Sep 5, 2014

In Brief

A Phase 3 clinical trial evaluating Keppra XR (Levetiracetam XR) for Epilepsy. Completed, enrolled 190 participants across 35 sites in 4 countries.

Detailed Summary

To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesMexico, Poland, Russia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 8, 2007
Enrollment StartDec 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.5 years ago

Interventions

Keppra XR (Levetiracetam XR)drug

500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).